Literature DB >> 1645426

[Risk of adrenal cortex insufficiency following heart transplantation].

M Hummel1, H Warnecke, S Schüler, K Luding, R Hetzer.   

Abstract

In 20 patients we studied the function of the corticotropic pituitary and adrenal gland 13 to 45 month (m = 27.1) after heart transplantation (HTx). For prophylactic immunosuppression all patients were treated with triple drug therapy, including Cyclosporine A, Azathioprine and Prednisolone. After performing the CRH-test we could demonstrate, that in all patients, treated with Prednisolone (0.09-0.15 mg/kg/day) for more than 1 year, adrenal insufficiency was evident. Patients must be controlled carefully, if therapy with steroids is stopped thereafter, not only because of increased risk of rejection but also because metabolic disturbance caused by adrenal insufficiency may occur. In case of elevated demand of steroids (i.e. infections or surgery), adequate substitution with glucocorticosteroids is needed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645426     DOI: 10.1007/bf01666853

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  17 in total

Review 1.  The immune-hypothalamic-pituitary-adrenal axis.

Authors:  A Bateman; A Singh; T Kral; S Solomon
Journal:  Endocr Rev       Date:  1989-02       Impact factor: 19.871

2.  [Corticotropin releasing factor (CRF): diagnostic aspects].

Authors:  O A Müller; G K Stalla; K von Werder
Journal:  Internist (Berl)       Date:  1985-05       Impact factor: 0.743

3.  Light synchronization of the circadian rhythm of plasma 11-hydroxycorticosteroids in man.

Authors:  P O Osterman
Journal:  Acta Endocrinol (Copenh)       Date:  1974-09

4.  The Registry of the International Society for Heart Transplantation: seventh official report--1990.

Authors:  J M Kriett; M P Kaye
Journal:  J Heart Transplant       Date:  1990 Jul-Aug

5.  Are steroids essential for successful maintenance of immunosuppression in heart transplantation?

Authors:  M R Katz; G R Barnhart; S Szentpetery; S Rider; J A Thompson; M Hess; A Hastillo; R R Lower
Journal:  J Heart Transplant       Date:  1987 Sep-Oct

6.  Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy.

Authors:  T H Schürmeyer; G C Tsokos; P C Avgerinos; J E Balow; R D'Agata; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1985-07       Impact factor: 5.958

Review 7.  Corticosteroid inhibition of ACTH secretion.

Authors:  M E Keller-Wood; M F Dallman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

8.  Direct measurement of human plasma corticotropin-releasing hormone by "two-site" immunoradiometric assay.

Authors:  E A Linton; C McLean; A C Nieuwenhuyzen Kruseman; F J Tilders; E A Van der Veen; P J Lowry
Journal:  J Clin Endocrinol Metab       Date:  1987-05       Impact factor: 5.958

9.  Immunoreactive corticotropin-releasing factor in human plasma.

Authors:  T Suda; N Tomori; F Yajima; T Sumitomo; Y Nakagami; T Ushiyama; H Demura; K Shizume
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

10.  Effects of adrenalectomy and dexamethasone administration on the level of prepro-corticotropin-releasing factor messenger ribonucleic acid (mRNA) in the hypothalamus and adrenocorticotropin/beta-lipotropin precursor mRNA in the pituitary in rats.

Authors:  H Jingami; S Matsukura; S Numa; H Imura
Journal:  Endocrinology       Date:  1985-10       Impact factor: 4.736

View more
  1 in total

Review 1.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.